ArticleBJGP open2026
Dispensing practices issue shorter prescription lengths compared with non-dispensing practices: a quasi-experimental cross-sectional study.
Article in BJGP open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDispensing practices, which have in-house dispensaries, are paid to dispense medications directly to patients. Evidence suggests that this financial incentive influences prescribing behaviour, although the underlying mechanisms remain unclear.
aimTo investigate the impact of dispensing status on prescription length in England. DESIGN &
settingQuasi-experimental, repeated-measures, cross-sectional study of English general practices.
methodBusiness administration data classified practices as dispensing or non-dispensing, determined the percentage of patients eligible for dispensing, and captured prescription lengths for seven drugs with fixed dosing regimens at 3-month intervals from July 2023 to April 2024. Generalised estimating equations analysed the relationship between dispensing status and the proportion of patients eligible for dispensing with average prescription length, controlling for patient and practice characteristics.
resultsAdjusting for patient and practice characteristics, dispensing practices prescribed shorter average lengths for all drugs. Desogestrel showed the largest difference (21.9 days shorter), followed by indapamide standard release (9.85 days), indapamide modified release (9.71 days), ezetimibe (8.41 days), tamsulosin (7.18 days), alendronic acid (6.63 days), and dapagliflozin (5.85 days). An increase in the proportion of patients eligible for dispensing was associated with significantly shorter prescription lengths across all drugs. Dispensing practices more consistently prescribed medications for 28-31 days, whereas non-dispensing practices showed greater variability.
conclusionDispensing practices are associated with shorter prescription lengths, increasing the number of prescriptions issued over time and the associated dispensing fee. The absence of clear guidance on prescription lengths likely contributes to this variability. Central bodies should consider providing explicit recommendations to optimise prescription durations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.